Details of the Drug Combination

General Information of Drug Combination (ID: DCULI8G)

Drug Combination Name
Oxytocin Etomidate
Indication
Disease Entry Status REF
Postpartum Hemorrhage Phase 1 [1]
Component Drugs Oxytocin   DMDL27I Etomidate   DMZI3WO
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Oxytocin
Disease Entry ICD 11 Status REF
Autism spectrum disorder 6A02 Approved [2]
Ductal breast carcinoma in situ N.A. Approved [3]
Postpartum haemorrhage JA43 Approved [3]
Lactation failure JB46.3 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Oxytocin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Agonist [7]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Agonist [8]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Agonist [9]
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Oxytocin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------
Indication(s) of Etomidate
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [6]
Etomidate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
GABA(A) receptor gamma-3 (GABRG3) TTEX6LM GBRG3_HUMAN Modulator [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03852797) Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
3 Oxytocin FDA Label
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
5 Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5463).
7 The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
9 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
11 Oxytocin inhibits ox-LDL-induced adhesion of monocytic THP-1 cells to human brain microvascular endothelial cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:104-110. doi: 10.1016/j.taap.2017.10.022. Epub 2017 Nov 2.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.